HER2阳性-话题@MedSci

#HER2阳性#

183篇内容 | 4820人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1308489, encodeId=41681308489bb, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=JCO：Her2阳性乳腺癌曲妥珠单抗治疗出现进展的方案探索, objectType=article, longId=98467, objectId=81bc9846eef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=81bc9846eef, replyNumber=0, likeNumber=58, createdTime=2017-05-12, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=81bc9846eef, moduleTitle=JCO：Her2阳性乳腺癌曲妥珠单抗治疗出现进展的方案探索, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=81bc9846eef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308488, encodeId=c39a13084886d, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=JAMA Surg：化疗后完全病理应答的HER2阳性及三阴性乳腺癌患者淋巴转移风险较低, objectType=article, longId=97071, objectId=262b9e07165, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=262b9e07165, replyNumber=0, likeNumber=65, createdTime=2017-04-27, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=262b9e07165, moduleTitle=JAMA Surg：化疗后完全病理应答的HER2阳性及三阴性乳腺癌患者淋巴转移风险较低, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=262b9e07165)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308487, encodeId=5b33130848ec2, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=ACCR年会：HER2靶向联合治疗对接受大量前期治疗的HER2阳性结直肠癌患者有效, objectType=article, longId=94574, objectId=4a4f945e447, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a4f945e447, replyNumber=0, likeNumber=48, createdTime=2017-04-05, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a4f945e447, moduleTitle=ACCR年会：HER2靶向联合治疗对接受大量前期治疗的HER2阳性结直肠癌患者有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a4f945e447)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308486, encodeId=d19313084864c, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=Lancet：曲妥珠单抗对HER2阳性早期乳腺癌的11年随访结果, objectType=article, longId=93431, objectId=b62a93431e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b62a93431e2, replyNumber=0, likeNumber=72, createdTime=2017-03-27, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b62a93431e2, moduleTitle=Lancet：曲妥珠单抗对HER2阳性早期乳腺癌的11年随访结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b62a93431e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308485, encodeId=a915130848519, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=The Lancet Oncology：曲妥珠单抗不能提高HER2阳性晚期胃癌患者的生存率, objectType=article, longId=93205, objectId=fef993205fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fef993205fc, replyNumber=0, likeNumber=27, createdTime=2017-03-25, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fef993205fc, moduleTitle=The Lancet Oncology：曲妥珠单抗不能提高HER2阳性晚期胃癌患者的生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fef993205fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308484, encodeId=9415130848414, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=JCO：二甲双胍可以显著改善HER2阳性早期乳腺癌合并糖尿病患者的预后, objectType=article, longId=92196, objectId=a0879219667, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a0879219667, replyNumber=0, likeNumber=0, createdTime=2017-03-18, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a0879219667, moduleTitle=JCO：二甲双胍可以显著改善HER2阳性早期乳腺癌合并糖尿病患者的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a0879219667)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308483, encodeId=c4d513084838b, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=Cancer Res：HDAC抑制剂可促进单抗药物对HER2阳性肿瘤的治疗效果, objectType=article, longId=90949, objectId=ebb19094974, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ebb19094974, replyNumber=0, likeNumber=78, createdTime=2017-03-08, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ebb19094974, moduleTitle=Cancer Res：HDAC抑制剂可促进单抗药物对HER2阳性肿瘤的治疗效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ebb19094974)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308482, encodeId=121513084828a, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=LANCET：使用曲妥珠单抗治疗HER2阳性早期乳腺癌患者维持多久疗效更佳？, objectType=article, longId=89829, objectId=3ab989829c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3ab989829c3, replyNumber=0, likeNumber=73, createdTime=2017-02-25, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3ab989829c3, moduleTitle=LANCET：使用曲妥珠单抗治疗HER2阳性早期乳腺癌患者维持多久疗效更佳？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3ab989829c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308481, encodeId=da54130848157, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=喜讯！罗氏乳腺癌新药Perjeta获英国NICE批准用于HER2阳性乳腺癌新辅助治疗, objectType=article, longId=86807, objectId=8ea08680e9d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ea08680e9d, replyNumber=0, likeNumber=49, createdTime=2017-01-07, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ea08680e9d, moduleTitle=喜讯！罗氏乳腺癌新药Perjeta获英国NICE批准用于HER2阳性乳腺癌新辅助治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8ea08680e9d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308480, encodeId=41061308480de, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=2016HER2阳性晚期胃癌分子靶向治疗的中国专家共识发布, objectType=article, longId=80314, objectId=1cdf80314fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1cdf80314fa, replyNumber=0, likeNumber=32, createdTime=2016-10-20, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1cdf80314fa, moduleTitle=2016HER2阳性晚期胃癌分子靶向治疗的中国专家共识发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1cdf80314fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308479, encodeId=3fec13084e97f, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=2016《HER2阳性乳腺癌临床专家共识》更新——助力推进乳腺癌规范化诊疗）发布, objectType=article, longId=74766, objectId=1fa0e47665c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1fa0e47665c, replyNumber=0, likeNumber=28, createdTime=2016-08-10, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1fa0e47665c, moduleTitle=2016《HER2阳性乳腺癌临床专家共识》更新——助力推进乳腺癌规范化诊疗）发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1fa0e47665c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308478, encodeId=fe4413084e8c1, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=Ann Oncol：肿瘤和免疫相关HER2阳性疾病对新辅助化疗加抗HER2药物反应的影响, objectType=article, longId=74602, objectId=fd1ee4602ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd1ee4602ba, replyNumber=0, likeNumber=69, createdTime=2016-08-08, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd1ee4602ba, moduleTitle=Ann Oncol：肿瘤和免疫相关HER2阳性疾病对新辅助化疗加抗HER2药物反应的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fd1ee4602ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308477, encodeId=4a8113084e73f, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=Cancer Biol Ther：中国学者发现黄连素可逆转HER2阳性乳腺癌细胞耐药, objectType=article, longId=73131, objectId=c5e3e313156, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c5e3e313156, replyNumber=0, likeNumber=82, createdTime=2016-07-20, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c5e3e313156, moduleTitle=Cancer Biol Ther：中国学者发现黄连素可逆转HER2阳性乳腺癌细胞耐药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c5e3e313156)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308476, encodeId=34f513084e6bb, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=NEJM：HER2阳性，激素受体阴性的乳腺癌患者使用来那替尼+标准治疗的缓解率更高, objectType=article, longId=72401, objectId=328fe24012e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=328fe24012e, replyNumber=0, likeNumber=59, createdTime=2016-07-10, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=328fe24012e, moduleTitle=NEJM：HER2阳性，激素受体阴性的乳腺癌患者使用来那替尼+标准治疗的缓解率更高, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=328fe24012e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308475, encodeId=143113084e55a, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=ASCO 2016：赫赛汀生物仿制药或可有效治疗HER2阳性的乳腺癌患者, objectType=article, longId=70016, objectId=04a8e0016c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04a8e0016c5, replyNumber=0, likeNumber=61, createdTime=2016-06-07, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04a8e0016c5, moduleTitle=ASCO 2016：赫赛汀生物仿制药或可有效治疗HER2阳性的乳腺癌患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=04a8e0016c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308474, encodeId=9d2f13084e41b, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=共识要点：HER2阳性乳腺癌临床诊疗专家共识, objectType=article, longId=67145, objectId=fe056e145d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe056e145d5, replyNumber=0, likeNumber=53, createdTime=2016-04-28, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe056e145d5, moduleTitle=共识要点：HER2阳性乳腺癌临床诊疗专家共识, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fe056e145d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308473, encodeId=e4e313084e3f3, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=HER2阳性乳腺小肿瘤须靶向治疗吗, objectType=article, longId=65929, objectId=648e65929c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=648e65929c3, replyNumber=0, likeNumber=68, createdTime=2016-04-03, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=648e65929c3, moduleTitle=HER2阳性乳腺小肿瘤须靶向治疗吗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=648e65929c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308472, encodeId=b39013084e270, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=JAMA Oncol：HER2阳性乳腺癌易致免疫缺陷促进癌症复发, objectType=article, longId=61768, objectId=84b261e688d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=84b261e688d, replyNumber=0, likeNumber=57, createdTime=2016-01-08, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=84b261e688d, moduleTitle=JAMA Oncol：HER2阳性乳腺癌易致免疫缺陷促进癌症复发, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=84b261e688d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308471, encodeId=2f7f13084e1c0, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=JCO：HER2阳性乳腺癌化疗——拉帕替尼并不优于曲妥单抗，反而增加了药毒性, objectType=article, longId=60124, objectId=d131601246f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d131601246f, replyNumber=0, likeNumber=67, createdTime=2015-12-05, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d131601246f, moduleTitle=JCO：HER2阳性乳腺癌化疗——拉帕替尼并不优于曲妥单抗，反而增加了药毒性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d131601246f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308470, encodeId=3e5513084e0a0, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=JAMA Oncol：肿瘤浸润淋巴细胞（TILs）可能是HER2阳性早期乳腺癌预后指标(NeoALTTO试验), objectType=article, longId=53522, objectId=0ee253522f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ee253522f6, replyNumber=0, likeNumber=94, createdTime=2015-07-21, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ee253522f6, moduleTitle=JAMA Oncol：肿瘤浸润淋巴细胞（TILs）可能是HER2阳性早期乳腺癌预后指标(NeoALTTO试验), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0ee253522f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

HER2阳性

2020-05-29

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

JCO：Her2阳性乳腺癌曲妥珠单抗治疗出现进展的方案探索

2017-05-12

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

JAMA Surg：化疗后完全病理应答的HER2阳性及三阴性乳腺癌患者淋巴转移风险较低

2017-04-27

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

ACCR年会：HER2靶向联合治疗对接受大量前期治疗的HER2阳性结直肠癌患者有效

2017-04-05

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

Lancet：曲妥珠单抗对HER2阳性早期乳腺癌的11年随访结果

2017-03-27

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

The Lancet Oncology：曲妥珠单抗不能提高HER2阳性晚期胃癌患者的生存率

2017-03-25

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

JCO：二甲双胍可以显著改善HER2阳性早期乳腺癌合并糖尿病患者的预后

2017-03-18

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

Cancer Res：HDAC抑制剂可促进单抗药物对HER2阳性肿瘤的治疗效果

2017-03-08

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

LANCET：使用曲妥珠单抗治疗HER2阳性早期乳腺癌患者维持多久疗效更佳？

2017-02-25

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

喜讯！罗氏乳腺癌新药Perjeta获英国NICE批准用于HER2阳性乳腺癌新辅助治疗

2017-01-07

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

2016HER2阳性晚期胃癌分子靶向治疗的中国专家共识发布

2016-10-20

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

2016《HER2阳性乳腺癌临床专家共识》更新——助力推进乳腺癌规范化诊疗）发布

2016-08-10

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

Ann Oncol：肿瘤和免疫相关HER2阳性疾病对新辅助化疗加抗HER2药物反应的影响

2016-08-08

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

Cancer Biol Ther：中国学者发现黄连素可逆转HER2阳性乳腺癌细胞耐药

2016-07-20

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

NEJM：HER2阳性，激素受体阴性的乳腺癌患者使用来那替尼+标准治疗的缓解率更高

2016-07-10

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

ASCO 2016：赫赛汀生物仿制药或可有效治疗HER2阳性的乳腺癌患者

2016-06-07

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

共识要点：HER2阳性乳腺癌临床诊疗专家共识

2016-04-28

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

HER2阳性乳腺小肿瘤须靶向治疗吗

2016-04-03

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

JAMA Oncol：HER2阳性乳腺癌易致免疫缺陷促进癌症复发

2016-01-08

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

JCO：HER2阳性乳腺癌化疗——拉帕替尼并不优于曲妥单抗，反而增加了药毒性

2015-12-05

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

JAMA Oncol：肿瘤浸润淋巴细胞（TILs）可能是HER2阳性早期乳腺癌预后指标(NeoALTTO试验)

2015-07-21

科室
- - 订阅+
  - 更多科室
工具
服务